

L Number	Hits	Search Text	DB	Time stamp
1	2948	allicin or aucubin or bilberry or caffeic or chlorogenic or echinacea or ferulic or lipoic or naringin or oleuropein or proanthocyanidin or quercetin or rutin	EPO; JPO; DERWENT	2002/07/22 13:17
2	39	(allicin or aucubin or bilberry or caffeic or chlorogenic or echinacea or ferulic or lipoic or naringin or oleuropein or proanthocyanidin or quercetin or rutin) and (ophthalm\$ or eye or (contact adj lens))	EPO; JPO; DERWENT	2002/07/22 13:18
3	1	1994-331246.NRAN.	DERWENT	2002/07/22 14:01
-	1	ep-252278-\$.did.	EPO; JPO; DERWENT	2002/06/11 15:21
-	1	1987-349580.NRAN.	DERWENT	2002/06/11 15:17
-	1	es-2118705-\$.did.	EPO; JPO; DERWENT	2002/06/11 15:21

(FILE 'HOME' ENTERED AT 14:10:16 ON 22 JUL 2002)

FILE 'CAPLUS, BIOSIS, MEDLINE, JAPIO' ENTERED AT 14:10:26 ON 22 JUL 2002

L1 52364 S ALLICIN OR AUCUBIN OR BILBERRY OR CAFFEIC OR CHLOROGENIC OR E
L2 212 S L1 AND (OPHTHALM? OR EYE OR (CONTACT LENS))

L5 ANSWER 86 OF 202 CAPLUS COPYRIGHT 2003 ACS
TI Anti-cataract effect of topical **quercetin** and myricetin in
galactosemic rats ^{5000 ppm}
AB Topical myricetin (0.1%) and **quercetin** (0.5%) delayed the onset
and development of cataracts in rats fed a diet contg. 30% galactose. The
levels of dulcitol, a polyalc. product of galactose, were lower in treated
than in control **eyes** on day 10, but not by day 40.
ACCESSION NUMBER: 1988:522462 CAPLUS
DOCUMENT NUMBER: 109:122462
TITLE: Anti-cataract effect of topical **quercetin**
and myricetin in galactosemic rats
AUTHOR(S): **Mohan, Madan;** Gupta, S. K.; Agnihotri, S.; Joshi, S.;
Uppal, A. K.
CORPORATE SOURCE: Dr. Rajendra Prasad Cent. Ophthalmic Sci., All-India
Inst. Med. Sci., New Delhi, 110 029, India
SOURCE: Medical Science Research (1988), 16(13), 685-6
CODEN: MSCREJ; ISSN: 0269-8951
DOCUMENT TYPE: Journal
LANGUAGE: English

DERWENT-ACC-NO: 1994-331246
DERWENT-WEEK: 199441
COPYRIGHT 1999 DERWENT INFORMATION LTD

TITLE: Anti-glaucoma prepn. synthesis - by dissolving adrenalin
hydro-tartrate
in borate buffer contg. mixt. of rutin, trilon B and acetyl-cysteine in
specific ratio

INVENTOR: CHAIKOVSKAYA, E A; ISTRANOV, L P

PATENT-ASSIGNEE: MOSC MED ACAD[MOMER]

PRIORITY-DATA: 1991SU-4936530 (May 14, 1991)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES
MAIN-IPC			
SU 1819613 A1	June 7, 1993	N/A	003 A61K 031/135

APPLICATION-DATA:

PUB-NO	APPL-DESCRIPTOR	APPL-NO
APPL-DATE		
SU 1819613A1	N/A	1991SU-4936530 May 14, 1991

INT-CL (IPC): A61K009/08; A61K031/135

ABSTRACTED-PUB-NO: SU 1819613A

BASIC-ABSTRACT: Antiglaucoma prepn. is obtd. by dissolving
adrenaline

hydrotartrate in a borate buffer contg. a mixt. (wt.%) of rutin (8-15),
Trilon

80-150 ppm

B (RTM) (8-10) and acetylcysteine (balance). This stabilising mixt. comprises 0.12-0.67% of the total soln. wt.. The soln., whose pH is adjusted to 6.5-7.5, is then filtered and sterilised.

USE - In ophthalmology.

ADVANTAGE - Adverse reactions and irritant effects are avoided.

Storage life

of antiglaucoma preps. may be increased to 2 years. The method can be used

to obtain 1% adrenaline solns. that resist oxidation under neutral pH conditions. Losses of excess soln. in the nasolacrimal canal that occur with

drop application of 0.18% adrenaline hydrotartrate solns. are prevented,

minimising waste. As a much larger proportion of the adrenaline exists in the

molecular form at pH 7.5, it is more readily absorbed by eye tissue.

CHOSEN-DRAWING: Dwg.0/0

TITLE-TERMS:

ANTI GLAUCOMA PREPARATION SYNTHESIS DISSOLVE

ADRENALIN HYDRO TARTRATE BORATE

BUFFER CONTAIN MIXTURE RUTIN TRILON ACETYL CYSTEINE
SPECIFIC RATIO

DERWENT-CLASS: B05

CPI-CODES: B06-A01; B10-B02D; B10-B03B; B12-M07; B14-N03;

CHEMICAL-CODES:

Chemical Indexing M2 *01*

Fragmentation Code

G015 G100 H1 H102 H181 H4 H402 H403 H442 H481

H482 H8 J0 J012 J1 J172 M210 M211 M273 M280
M281 M312 M321 M332 M343 M344 M349 M373 M381 M391
M414 M416 M431 M510 M520 M531 M540 M620 M650 M782
M903 M904 P922
Markush Compounds
199441-30101-M

Chemical Indexing M2 *02*

Fragmentation Code
D014 D023 D120 F012 F013 F014 F015 F016 F019 F123
F199 G015 G100 H4 H405 H424 H444 H5 H522 H8
J5 J521 K0 L8 L814 L817 L822 L831 L9 L960
M1 M113 M126 M141 M210 M211 M240 M281 M311 M321
M342 M373 M391 M412 M431 M511 M522 M531 M540 M782
M903 M904 M910 P922
Specific Compounds
01179M
Registry Numbers
1179U

Chemical Indexing M2 *03*

Fragmentation Code
H1 H103 H182 J0 J014 J1 J173 M280 M311 M312
M321 M323 M332 M342 M349 M381 M383 M391 M393 M416
M431 M620 M782 M903 M904 M910 P922
Specific Compounds
03804M
Registry Numbers
0195U

Chemical Indexing M2 *04*

Fragmentation Code
H4 H498 H9 J0 J012 J1 J171 J3 J371 M210
M211 M262 M281 M312 M321 M332 M343 M349 M381 M391
M416 M431 M620 M782 M903 M904 P922
Specific Compounds
04369M

UNLINKED-DERWENT-REGISTRY-NUMBERS: 0195U; 1179U

SECONDARY-ACC-NO:

CPI Secondary Accession Numbers: C1994-150857

DERWENT-ACC-NO: 1985-297001
DERWENT-WEEK: 198548
COPYRIGHT 1999 DERWENT INFORMATION LTD

TITLE: Vitamin=E ointments, gels, creams and drops use - for
protection of
eyes against oxygen and free radicals and treatment and prophylaxis
of
inflammatory processes

INVENTOR: ISMAIL, M R

PATENT-ASSIGNEE: ISMAIL M R[ISMAI]

PRIORITY-DATA: 1984DE-3416209 (May 2, 1984)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES
MAIN-IPC			
DE 3416209 A	November 21, 1985	N/A	010 N/A
DE 3584909 G	January 30, 1992	N/A	000 N/A
EP 163924 A	December 11, 1985	E	000 N/A
EP 163924 B	December 18, 1991	N/A	000 N/A

DESIGNATED-STATES: AT BE CH DE FR GB IT LU NL SE AT BE
CH DE FR GB IT LI LU NL S
E

CITED-DOCUMENTS: FR 2420973; GB 1453239 ; EP 151987 ; EP
151989 ; EP 152106
; EP 158090 ; WO 8401899

INT-CL (IPC): A61K009/06; A61K031/35

ABSTRACTED-PUB-NO: DE 3416209A

BASIC-ABSTRACT: Protection of the eyes against injurious oxygen oxidn. and against injurious radicals, and treatment and prophylaxis of inflammatory processes, using vitamin E-contg. ointments, gels, creams or drops with usual carriers and adjuvants are new.

Vitamin E is pref. in the form of dl-alpha-tocopherol, D-alpha-tocopherol or D-alpha-tocopherol concentrate. Vitamin A (if present) can e.g. be in the form of vitamin A palmitate or acetate. Other active ingredients can include B series vitamins (e.g. thiamine HCl, riboflavin 5-phosphate, cyanocobalamin), ascorbic acid, berberine hydrochloride, naphazoline, dexpanthenol, calcium pantothenate, sodium D-pantothenate, digitalis, aesculin, sodium iodide, rubidium iodide, calcium iodide, oil of fennel, rose oil or oil of balm.

ADVANTAGE - When applied to the eyes, vitamin E penetrates into the inner eye. Similar effects are observed when the preparations are applied to the nasal mucosa and to mucous membranes generally. When the preparations also contain vitamin A, the beneficial effects of vitamin A are potentiated.

ABSTRACTED-PUB-NO: EP 163924B

EQUIVALENT-ABSTRACTS: The use of vitamin E in combination with one or more blood circulation-promoting agent(s) and/or vitamin A, optionally with one or

more substances from the group of the vitamins of the B series,
vitamin C,
preservatives, conventional carriers and excipients for the preparation
of a
medicament for the external treatment of the mucous membranes of
the eyes, of
the nose and of the throat and pharynx region in cases of allergies and
colds.
(10pp)

CHOSEN-DRAWING: Dwg.0/0

TITLE-TERMS:

VITAMIN=E OINTMENT GEL CREAM DROP PROTECT EYE
OXYGEN FREE RADICAL TREAT
PROPHYLACTIC INFLAMMATION PROCESS

DERWENT-CLASS: B05

CPI-CODES: B03-H; B12-D07; B12-L04;

CHEMICAL-CODES:

Chemical Indexing M2 *01*

Fragmentation Code

D012 D016 D025 D120 H4 H401 H441 H8 M210 M211

M225 M232 M240 M283 M320 M412 M511 M520 M530 M540

M781 M903 M910 P420 P922 Q624 V0 V350

UNLINKED-DERWENT-REGISTRY-NUMBERS: 0179U

SECONDARY-ACC-NO:

CPI Secondary Accession Numbers: C1985-128534

DERWENT-ACC-NO: 1988-358519
DERWENT-WEEK: 198850
COPYRIGHT 1999 DERWENT INFORMATION LTD

TITLE: Anti-allergic eye lotions, for allergic conjunctivitis - contg.
specific effective concn. of cyclo-heptadiene or its salts

PATENT-ASSIGNEE: SANTEN SEIYAKU KK[SANT]

PRIORITY-DATA: 1987JP-0106877 (April 30, 1987)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES
MAIN-IPC			
JP 63270625 A	November 8, 1988	N/A	003 N/A

APPLICATION-DATA:

PUB-NO	APPL-DESCRIPTOR	APPL-NO
APPL-DATE		
JP63270625A	N/A	1987JP-0106877 April 30, 1987

INT-CL (IPC): A61K031/49; C07D211/14

ABSTRACTED-PUB-NO: JP63270625A

BASIC-ABSTRACT: Antiallergic eye lotions contain effective concn. of cycloheptadine or its salts. Pref. the salt of cycloheptadine is cycloheptadine hydrochloride. The concn. of cycloheptadine is 0.01% or more.

pH of the lotion is 4.5-8. Other additives (e.g. paraoxybenzoic acid ester, benzalkonium chloride, sodium-phosphate or -hydroxide) can be used for the lotions. The lotions can contain other eye medicines (e.g. anphazoline

hydrochloride, berberine chloride or sodium azulene sulphonate).

USE - For allergic conjunctivitis In an example, (1) cycloheptadiene hydrochloride of (0.05 g) and boric acid of (1.8 g) are dissolved in refined water (80 ml). 1% benzalkonium chloride soln. (0.5 ml) and sodium hydroxide are added to the mixt. with additional refined water (total: 100 ml).

Eye

lotion (100 ml) comprises cycloheptadine (of 0.1 g), propyleneglycol (of 2.0 g), benzalkonium chloride (of 0.005 g), sodium hydroxide and sterile water

(balance). Eye lotion (100 ml) comprises cycloheptadine (of 0.2 g), D-mannitol

(of 2.0 g), Iglycerine (of 1.3 g), benzalkonium chloride (of 0.005 g), sodium hydroxide and sterile water (balance).

CHOSEN-DRAWING: Dwg.0/0

TITLE-TERMS:

ANTI ALLERGIC EYE LOTION ALLERGIC CONJUCTIVA CONTAIN
SPECIFIC EFFECT
CONCENTRATE CYCLO HEPTADIENE SALT

DERWENT-CLASS: B03

CPI-CODES: B07-D05; B12-D02; B12-L04; B12-M02B;

CHEMICAL-CODES:

Chemical Indexing M2 *01*

Fragmentation Code

F011 F014 F433 G031 G360 H1 H181 H2 H201 H7

H720 M1 M116 M210 M211 M273 M281 M320 M413 M431

M510 M521 M531 M540 M640 M782 M903 M904 M910 P431

P922 R023

Specific Compounds

01092M 13364M

Registry Numbers

3102R 1678D

Chemical Indexing M2 *02*

Fragmentation Code

F012 F522 G020 G221 M1 M125 M132 M280 M311 M321

M342 M413 M431 M510 M521 M531 M540 M640 M782 M903

M904 P431 P922 R023

Specific Compounds

04546M

Registry Numbers

3102R 1678D

Chemical Indexing M2 *03*

Fragmentation Code

D023 E570 H5 H542 H8 K0 L7 L721 M210 M211

M272 M282 M320 M412 M431 M511 M520 M530 M540 M782

M903 M904 P431 P922 R023 V0 V470

Ring Index

05835

Specific Compounds

16097M

Registry Numbers

3102R 1678D

Chemical Indexing M2 *04*

Fragmentation Code

G000 G031 G650 K0 K4 K432 M280 M320 M415 M431

M510 M520 M530 M541 M610 M630 M782 M903 M904 M910

P431 P922 R023

Specific Compounds

16098M

Registry Numbers

3102R 1678D

Chemical Indexing M2 *05*

Fragmentation Code

G013 G100 H4 H401 H441 H8 J0 J011 J2 J231
M210 M211 M212 M213 M214 M215 M216 M220 M221 M222
M231 M232 M233 M272 M281 M320 M414 M431 M510 M520
M531 M540 M782 M903 M904 P922 R023

Markush Compounds

198850-19501-M

Registry Numbers

3102R 1678D

Chemical Indexing M2 *06*

Fragmentation Code

G010 G100 H1 H181 K0 L7 L722 M210 M211 M220
M222 M223 M224 M225 M231 M232 M233 M273 M283 M311
M321 M342 M373 M391 M414 M431 M510 M520 M531 M540
M782 M903 M904 M910 P922 R023

Specific Compounds

03054M

Registry Numbers

3102R 1678D

Chemical Indexing M2 *07*

Fragmentation Code

A111 A940 B115 B701 B713 B720 B815 B831 C101 C108
C802 C804 C805 C807 M411 M431 M782 M903 M904 M910
P922 R023

Specific Compounds

01689M

Registry Numbers

3102R 1678D

Chemical Indexing M2 *08*

Fragmentation Code

A111 A940 B115 B701 B713 B720 B815 B831 C101 C108
C802 C804 C805 C807 M411 M431 M782 M903 M904 M910
P922 R023

Specific Compounds

01688M

Registry Numbers

3102R 1678D

Chemical Indexing M2 *09*

Fragmentation Code

A111 A940 B115 B701 B713 B720 B815 B831 C108 C802

C803 C804 C805 C807 M411 M431 M782 M903 M904 M910

P922 R023

Specific Compounds

01690M

Registry Numbers

3102R 1678D

Chemical Indexing M2 *10*

Fragmentation Code

A111 A940 C101 C108 C550 C730 C801 C802 C804 C805

C807 M411 M431 M782 M903 M904 M910 P922 R023

Specific Compounds

01514M

Registry Numbers

3102R 1678D

Chemical Indexing M2 *11*

Fragmentation Code

B105 B713 B720 B803 B831 C101 C108 C800 C802 C804

C805 C807 M411 M431 M782 M903 M904 M910 P922 R023

Specific Compounds

01894M

Registry Numbers

3102R 1678D

Chemical Indexing M2 *12*

Fragmentation Code

H4 H402 H482 H8 M280 M313 M321 M331 M342 M383

M391 M416 M431 M620 M782 M903 M904 M910 P922 R023

Specific Compounds

00137M

Registry Numbers

3102R 1678D

Chemical Indexing M2 *13*

Fragmentation Code

H4 H405 H484 H8 K0 L8 L816 L821 L833 M280

M315 M321 M332 M344 M383 M391 M416 M431 M620 M782

M800 M903 M904 M910 P922 R023

Specific Compounds

07423M

Registry Numbers

3102R 1678D

Chemical Indexing M2 *14*

Fragmentation Code

H4 H403 H483 H8 M280 M313 M321 M332 M343 M383

M391 M416 M431 M620 M782 M903 M904 M910 P922 R023

Specific Compounds

00113M

Registry Numbers

3102R 1678D

UNLINKED-DERWENT-REGISTRY-NUMBERS: 0113U; 0137U ;

0290U ; 1092U ; 1187U ; 1514U

; 1688U ; 1689U ; 1690U ; 1832U ; 1894U

SECONDARY-ACC-NO:

CPI Secondary Accession Numbers: C1988-158766